Sigachi Industries pushes back CCS facility timeline to Q1 FY28
Management deferred the CCS project commissioning while insurance claims at the Hyderabad plant face fresh delays, clouding the FY27 recovery path.
What's new
- CCS facility commercialization pushed to Q1 FY28.
- Insurance payout on Hyderabad plant delayed to June 30.
- FY27 revenue guidance set at ₹650-675 cr, a 35% growth target.
- Dahej MCC capacity expansion expected online in Q2 FY27.
Themes from the call
Demand
Customer stickiness remains high, with formulation companies returning to Sigachi as production capacity scales back toward pre-accident levels.
Margins
EBITDA margins are projected to recover to 18-20% by year-end as safety costs stabilize and utilization at the new Dahej facility improves.
Capital allocation
Funding for the ₹200 cr capex program remains unclear, with management describing the debt-equity mix as a fluid state.
Guidance watch
- Revenue guidance for FY27 is ₹650-675 cr, contingent on the Q2 FY27 launch of the 12,000 MT Dahej facility.
Risk flags
- The Hyderabad plant restart remains stalled by sub-judice proceedings, and insurance payout timelines have already slipped once.
- Management has not disclosed the financing mix for its ₹200 cr capex requirements, creating uncertainty over potential equity dilution.
Key quotes
-
"The 12,000 metric ton expansion is expected to generate Rs 220 crores in revenue, and CCS can generate around Rs 100 crores."
— Amit Raj Sinha, Managing Director -
"We expected this during March, but there is a slight delay in the procedure. By the end of June, we are expecting some ad-hoc amount."
— Amit Raj Sinha, Managing Director
The brief
Sigachi Industries is grappling with operational and administrative friction. While the company aims to reclaim its 18-20% margin profile by the end of FY27, management's ability to stick to its own schedule is wavering. The most immediate example is the 1,800-ton CCS facility, which has been delayed from Q3 FY27 to Q1 FY28 without a clear explanation.
Simultaneously, the promised insurance payout from the June 2025 Hyderabad plant accident has been pushed to June 30, 2026. Management is currently prioritizing the Dahej expansion over the Hyderabad restart, essentially doubling down on new capacity to replace the lost output. This shift in strategy is a necessary response to legal constraints, but it adds pressure on the balance sheet. With ₹200 cr in capex planned for the near term, the lack of clarity on how this will be funded—debt or equity—remains a significant overhang.
The underlying demand story appears intact. Sigachi’s customers are returning as production normalizes, and the API segment is showing promise with its move toward high-margin Cystic Fibrosis products. However, the company is in a transition phase where the cost of stabilizing operations is weighing on profitability. The Q4 margin of 12.63% is a starting point, and hitting the 18-20% year-end target requires perfect execution on the Dahej ramp-up. Investors are effectively being asked to trust a recovery that is already running behind schedule.
Sigachi's growth story is clear, but its timeline is slipping. Until the capex funding and CCS launch dates stabilize, the promised margin recovery remains a moving target.